312 related articles for article (PubMed ID: 32483735)
1. Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.
DeRenzo C; Gottschalk S
Adv Exp Med Biol; 2020; 1257():109-131. PubMed ID: 32483735
[TBL] [Abstract][Full Text] [Related]
2. Genetically modified T-cell therapy for osteosarcoma.
DeRenzo C; Gottschalk S
Adv Exp Med Biol; 2014; 804():323-40. PubMed ID: 24924183
[TBL] [Abstract][Full Text] [Related]
3. Current status and future challenges of CAR-T cell therapy for osteosarcoma.
Li S; Zhang H; Shang G
Front Immunol; 2023; 14():1290762. PubMed ID: 38187386
[TBL] [Abstract][Full Text] [Related]
4. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
5. CAR T targets and microenvironmental barriers of osteosarcoma.
Zhu J; Simayi N; Wan R; Huang W
Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
Yu T; Jiang W; Wang Y; Zhou Y; Jiao J; Wu M
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38390935
[TBL] [Abstract][Full Text] [Related]
7. Potential of human γδ T cells for immunotherapy of osteosarcoma.
Li Z
Mol Biol Rep; 2013 Jan; 40(1):427-37. PubMed ID: 23065272
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.
Rainusso N; Brawley VS; Ghazi A; Hicks MJ; Gottschalk S; Rosen JM; Ahmed N
Cancer Gene Ther; 2012 Mar; 19(3):212-7. PubMed ID: 22173710
[TBL] [Abstract][Full Text] [Related]
9. Promise and Challenges of T Cell Immunotherapy for Osteosarcoma.
Park JA; Cheung NV
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569894
[TBL] [Abstract][Full Text] [Related]
10. A Review of T-Cell Related Therapy for Osteosarcoma.
Yoshida K; Okamoto M; Aoki K; Takahashi J; Saito N
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664248
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
13. Adoptive CD8
Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
15. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
16. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
17. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
18. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.
Mensali N; Köksal H; Joaquina S; Wernhoff P; Casey NP; Romecin P; Panisello C; Rodriguez R; Vimeux L; Juzeniene A; Myhre MR; Fåne A; Ramírez CC; Maggadottir SM; Duru AD; Georgoudaki AM; Grad I; Maturana AD; Gaudernack G; Kvalheim G; Carcaboso AM; de Alava E; Donnadieu E; Bruland ØS; Menendez P; Inderberg EM; Wälchli S
Nat Commun; 2023 Jun; 14(1):3375. PubMed ID: 37291203
[TBL] [Abstract][Full Text] [Related]
19. Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.
Leung W; Heslop HE
Cancer Immunol Res; 2019 Apr; 7(4):528-533. PubMed ID: 30936089
[TBL] [Abstract][Full Text] [Related]
20. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
